Kiromic BioPharma Long Term Debt

Kiromic BioPharma (KRBP) currently reports a long-term debt of $230K as of December 2024. That compares with $910K in the prior-year period — down 75.0% year over year. Use the charts on this page to explore Kiromic BioPharma's long-term debt history and peer comparisons.

Kiromic BioPharma's long-term debt decreased from $910K to $230K — a 75.0% year-over-year decrease (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kiromic BioPharma reported $230K in long-term debt as of December 2024. That compares with $910K in the prior-year period — down 75.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $230K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kiromic BioPharma, and consider following KRBP for alerts when major investors trade the stock.

Kiromic BioPharma is classified in the Healthcare sector. On long-term debt, it currently shows $230K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRBP with unrelated industries.